Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raffaele Addeo

Showing results (1-10 of 108) with videos related to

Pageof 11
Sort By:
Expert Review of Anticancer Therapy|January 28, 2017
A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1)Raffaele Addeo
Journal of Experimental Pharmacology|October 6, 2021
Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung CancerRaffaele Addeo
Expert Opinion on Investigational Drugs|May 3, 2011
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?Raffaele Addeo, Michele Caraglia
Chinese Clinical Oncology|January 6, 2026
Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiationAurora Mirabile, Raffaele Addeo
Expert Review of Anticancer Therapy|February 24, 2011
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?Raffaele Addeo, Michele Caraglia
Expert Opinion on Biological Therapy|July 14, 2016
Pembrolizumab: the value of PDL1 biomarker in head and neck cancerRaffaele Addeo, Michele Caraglia, Giada Iuliano
International Journal of Molecular Sciences|July 12, 2025
New Anticancer Agents: Design, Synthesis and EvaluationVadim Pokrovsky, Raffaele Addeo, Mauro Coluccia
Expert Review of Anticancer Therapy|May 11, 2024
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?Pasquale Vitale, Vincenzo De Falco, Raffaele Addeo
Expert Opinion on Investigational Drugs|February 27, 2009
Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, ItalyRaffaele Addeo, Michele Caraglia, Salvatore Del Prete
Cancer Biology & Therapy|July 10, 2009
MUC2: a new key for pancreas cancer prognosisRaffaele Addeo, Alberto Abbruzzese, Salvatore Del Prete
Pageof 11

Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Expert Review of Anticancer Therapy|January 28, 2017
A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1)Raffaele Addeo
Journal of Experimental Pharmacology|October 6, 2021
Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung CancerRaffaele Addeo
Expert Opinion on Investigational Drugs|May 3, 2011
Combining temozolomide with other antitumor drugs and target-based agents in the treatment of brain metastases: an unending quest or chasing a chimera?Raffaele Addeo, Michele Caraglia
Chinese Clinical Oncology|January 6, 2026
Enhancing audiometric surveillance in head and neck cancer patients undergoing cisplatin-based chemoradiationAurora Mirabile, Raffaele Addeo
Expert Review of Anticancer Therapy|February 24, 2011
The oral tyrosine kinase inhibitors lapatinib and sunitinib: new opportunities for the treatment of brain metastases from breast cancer?Raffaele Addeo, Michele Caraglia
Expert Opinion on Biological Therapy|July 14, 2016
Pembrolizumab: the value of PDL1 biomarker in head and neck cancerRaffaele Addeo, Michele Caraglia, Giada Iuliano
International Journal of Molecular Sciences|July 12, 2025
New Anticancer Agents: Design, Synthesis and EvaluationVadim Pokrovsky, Raffaele Addeo, Mauro Coluccia
Expert Review of Anticancer Therapy|May 11, 2024
Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?Pasquale Vitale, Vincenzo De Falco, Raffaele Addeo
Expert Opinion on Investigational Drugs|February 27, 2009
Highlights of regional meeting of Italian Southern Oncological Group (GOIM): focus on hepatocellular carcinoma: biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, ItalyRaffaele Addeo, Michele Caraglia, Salvatore Del Prete
Cancer Biology & Therapy|July 10, 2009
MUC2: a new key for pancreas cancer prognosisRaffaele Addeo, Alberto Abbruzzese, Salvatore Del Prete
Pageof 11